Biosynex

ALBIO

FR0011005933

Medical Equipment, Supplies & Distribution

Market Closed - Euronext Paris Other stock markets 11:35:19 2025-06-12 am EDT			5-day change	1st Jan Change
1.290 ^EUR	-1.90%		0.00%	-25.00%

Apr. 29	Biosynex SA Reports Earnings Results for the Full Year Ended December 31, 2024	CI
Jan. 21	Biosynex SA announced that it expects to receive ?7.987161 million in funding	CI

Biosynex SA announced that it expects to receive ?7.987161 million in funding

Published on 01/21/2025 at 18:00

BIOSYNEX SA announced a private placemen to issue 7,987,161 common shares at an issue price of ?1 per share for the gross proceeds of ?7,987,161 on January 22, 2025.

Latest news about Biosynex

Biosynex SA Reports Earnings Results for the Full Year Ended December 31, 2024	Apr. 29	CI
Biosynex SA announced that it expects to receive ?7.987161 million in funding	Jan. 21	CI
Biosynex SA Reports Earnings Results for the Half Year Ended June 30, 2024	Nov. 03	CI
Biosynex SA Reports Earnings Results for the Full Year Ended December 31, 2023	24-04-30	CI
Biosynex SA Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-29	CI
Biosynex Unit to Acquire US-based Biotech Qualigen	23-07-21	MT
Biosynex SA acquired 57.33% interest in ProciseDx Inc. from Nestlé HealthCare Nutrition, Inc., other shareholders, employees, former employees and investors.	23-06-12	CI
Biosynex SA signed an agreement to acquire 57.33% interest in ProciseDx Inc. from NestlÃ© HealthCare Nutrition, Inc., other shareholders, employees, former employees and investors.	23-06-11	CI
Biosynex SA acquired Eye Care activity from LABORATOIRES INNOXA.	23-06-07	CI
Biosynex SA completed the acquisition of Chembio Diagnostics, Inc. from Perceptive Advisors LLC and others.	23-04-26	CI
Global markets live: EssilorLuxottica, AT&T, Tesla, Credit Suisse, Sony...	23-04-21
Biosynex SA Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-20	CI
Chembio Diagnostics Tender Offer Expiration Extended by Biosynex	23-04-13	MT
Biosynex Unit Extends Expiration Time of Tender Offer for Chembio Diagnostics Shares; Stock Rises	23-03-29	MT
Chembio Diagnostics Agrees to $17.2 Million Takeover by Biosynex; Shares Rise Pre-Bell	23-02-01	MT
Biosynex SA completed the acquisition of additional 46.52% stake in Theradiag SA for €21.6 million.	23-01-30	CI
Biosynex SA entered into a definitive merger agreement to acquire Chembio Diagnostics, Inc. for $17.2 million.	23-01-30	CI
Biosynex Sa Extend Distribution Agreement with Credo Diagnostics Biomedical Pte Ltd	23-01-12	CI
Biosynex SA completed the acquisition of 40% stakes in Theradiag SA.	23-01-11	CI
Biosynex SA acquired 75% stake in Medkoncept A/S.	22-12-20	CI
Biosynex SA Reports Earnings Results for the Half Year Ended June 30, 2022	22-10-20	CI
Biosynex SA acquired Doc2u SAS on October 12, 2022.	22-10-11	CI
French Diagnostics Company Biosynex Offers to Take Over Theradiag	22-09-23	MT
Biosynex SA bid to acquire remaining 74.93% stakes in Theradiag SA.	22-09-22	CI
Biosynex SA agreed to acquire Bigix Pharma Srl.	22-09-21	CI

Biosynex specializes in the research, development and manufacturing of fast diagnosis tests on membrane support for health professionals (biologists, clinicians, nurses and midwives). Products are used in the tropical diseases, autoimmune diseases, emergency markers and Infectious diseases fields. The company's activity is organized around 5 areas: - manufacturing of diagnosis tests for own account; - sale of diagnosis tests supplied by other manufacturers of semi-finished products; - research and development services for third party; - sale of licenses; - sale of biological reagents.

Employees

476

Sector

Medical Equipment, Supplies & Distribution

More about the company